Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases

Schoch, Kathleen M., Miller, Timothy M.·2017·Neuron
DOI 10.1016/j.neuron.2017.04.010

Cited by (274)

Items 201–274 of 274

  1. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions
    Jin Hong, Vivek K. Rajwanshi · 2025 · Antiviral Research
  2. CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways
    Karl E. Johansson, Amal Maouia, Johan Rebetz, Geneviève Marcoux, Oonagh Shannon, Joseph E. Italiano, Padma Narayanan, Scott P. Henry, Lijiang Shen, John W. Semple · 2024 · Journal of Thrombosis and Haemostasis
  3. Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example
    Juliana Inês Santos, Mariana Gonçalves, Liliana Matos, Luciana Moreira, Sofia Carvalho, Maria João Prata, Maria Francisca Coutinho, Sandra Alves · 2022 · Life
  4. The Role of Human Pluripotent Stem Cells in Amyotrophic Lateral Sclerosis: From Biological Mechanism to Practical Implications
    Laura Ceccarelli, Lorenzo Verriello, Giada Pauletto, Mariarosaria Valente, Leopoldo Spadea, Carlo Salati, Marco Zeppieri, Tamara Ius · 2024 · Frontiers in Bioscience-Landmark
  5. Frontiers of Neurodegenerative Disease Treatment: Targeting Immune Cells in Brain Border Regions
    Senthil Kumaran Satyanarayanan, Zixu Han, Jingwei Xiao, Qiuju Yuan, Wing‐Ho Yung, Ya Ke, Raymond Chuen‐Chung Chang, Maria Huachen Zhu, Huanxing Su, Kuan Pin Su et al. · 2024 · Brain Behavior and Immunity
  6. In Vivo Administration of Therapeutic Antisense Oligonucleotides
    Luisa Statello, Mohamad Moustafa Ali, Chandrasekhar Kanduri · 2020 · Methods in molecular biology
  7. Pyrrole–Imidazole Polyamides – A Frontrunner in Nucleic Acid‐Based Small Molecule Drugs
    Thangavel Vaijayanthi, Ganesh N. Pandian, Hiroshi Sugiyama · 2023 · Advanced Therapeutics
  8. Antisense oligonucleotide-mediated terminal intron retention of endoglin: A potential strategy to inhibit renal interstitial fibrosis
    Tessa Gerrits, Kyra L. Dijkstra, Jan Anthonie Bruijn, Marion Scharpfenecker, Roel Bijkerk, Hans J. Baelde · 2024 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  9. Lattice Corneal Dystrophy
    Majid Moshirfar, William B. West, Yasmyne C. Ronquillo · 2021 · StatPearls
  10. Antisense Oligonucleotide Therapeutics for Neurodegenerative Disorders
    Claudia M. Testa · 2021 · Current Geriatrics Reports
  11. Antisense‐induced knockdown of cAMP response element‐binding protein downregulates Per1 gene expression in the shell region of nucleus accumbens resulting in reduced alcohol consumption in mice
    Rishi Sharma, Vaibhav Kumar Mishra, Meet S Parikh, Anshul Soni, Pradeep Kumar Sahota, Mahesh M. Thakkar · 2021 · Alcoholism Clinical and Experimental Research
  12. Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference
    Yue Wang, Xiujue Zheng, Jun Liu, Li Chen, Qixian Chen, Yan Zhao · 2022 · Journal of Colloid and Interface Science
  13. The Novel LncRNA WASH5P Inhibits Colorectal Cancer Carcinogenesis via Targeting AKT Signaling Pathway
    Hongyun Wei, Tao Mao, Qian Zhang, Keyu Ren, Xingsi Qi, Yunmei Zhang, Bin Cao, Yanchun Jin, Zibin Tian, Linlin Ren · 2022 · Frontiers in Oncology
  14. Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases
    Xiyuan Lin, Li Chen, Keran Jia, Shengbiao Li, Qiuhong Li, Jingyan Yi, Jinshan Xing · 2026 · International Journal of Nanomedicine
  15. Antisense Oligonucleotides in Parkinson's Disease: Challenges, Opportunities, and the Promise of Low‐Intensity Focused Ultrasound for Brain Delivery
    Shunsuke Obika, Javier Blesa · 2026 · Journal of Neurochemistry
  16. Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?
    B.D. Bax, Dmitry A. Sutormin, Neil Q. McDonald, Glenn A. Burley, Tatyana A. Shelkovnikova · 2022 · International Journal of Molecular Sciences
  17. CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD
    Sarah R. Pickles, Desiree Zanetti Alepuz, Yuka Mitsuhashi Koike, Mei Yue, Jimei Tong, Pinghu Liu, Yugui Zhou, Karen R. Jansen‐West, Lillian M. Daughrity, Yuping Song et al. · 2023 · Frontiers in Cell and Developmental Biology
  18. A brief review of ALS from an immunological perspective with potential immunotherapy options
    Gülsüm Ayhan, Esra Aydemir, Furkan Ayaz · 2025 · Discover Immunity.
  19. Enhancing the delivery of SOD1 antisense oligonucleotides to the murine brain using lipid nanoparticles and image-guided focused ultrasound
    Gayathri R. Ediriweera, Nicholas L. Fletcher, Gary Cowin, Joshua D. Simpson, Liyu Chen, Joanna Marta Wasielewska, Jeremy Stephen Lum, Luke McAlary, Mikayla L. Brown, Justin J. Yerbury et al. · 2022 · Research Square
  20. PROGRESS OF OLIGONUCLEOTIDE THERAPEUTICS TARGET TO RNA
    Yufei Pan, Xinyang Zhou, Zhenjun Yang · 2022 · Wiley eBooks
  21. Terra incognita of glial cell dynamics in the etiology of leukodystrophies: Broadening disease and therapeutic perspectives
    Rishabh Chaudhary, Mujeeba Rehman, Vipul Agarwal, Anand Kumar, Arjun Singh Kaushik, Siddhi Srivastava, Sukriti Srivastava, Rajkumar Verma, Paruvathanahalli Siddalingam Rajinikanth, Vikas Mishra · 2024 · Life Sciences
  22. ClinASO: An open-source platform for rapid drug discovery of gapmer antisense oligonucleotides
    Shunkai Chen, Hao Liu, Dezi Cong, Ao Dong, Yuhang Wang, Jingyi Bi, Shijie Guo, Juan Yang, Xiaolei Wang, Guiping Ren et al. · 2026 · Molecular Therapy — Nucleic Acids
  23. Ext1-targeted gene therapy ameliorates tauopathy by inhibiting heparan sulfate-dependent tau propagation
    Rongyao Huang, Xiaoxun Ye, Jiayi Liu, Chunyan Yang, Xiaoya Meng, Tingting Dou, Xiaoqing Zhuang, Jinghan Yang, Naizhen Zheng, Yang Zhao et al. · 2026 · Pharmacological Research
  24. Amyloidosis of the heart: pathophysiology, diagnosis, and treatment
    Andy Yi-Yang Wang, Uzair Mahmoud, Jared M. Feldman, Stephen Pan, Wilbert S. Aronow, Diwakar Jain · 2025 · Expert Opinion on Pharmacotherapy
  25. Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling
    Alper Yavas, Maaike van Putten, Annemieke M Aartsma-Rus · 2024 · Journal of Neuromuscular Diseases
  26. Antisense Oligonucleotides in Psychiatric Disorders
    Heiko Graf, Claudia D. Wurster · 2018 · Journal of Clinical Psychopharmacology
  27. Genspezifische Therapien neurologischer Erkrankungen – aktueller Stand und Perspektiven
    Dávid Brenner, Albert Christian Ludolph · 2020 · Der Nervenarzt
  28. Advances in the understanding of hereditary ataxia – implications for future patients
    Anna Maria Zeitlberger, Heather Ging, Suran Nethisinghe, Paola Giunti · 2018 · Expert Opinion on Orphan Drugs
  29. Enclosure of siRNA in Alternately Hydrophilic–Hydrophobic Double-Layered Nanoarchitectures for Promoted RNAi
    Jinxuan He, Zhixiang Mou, Yuchen Tian, Liangping Yu, Tianjun Guan, Qixian Chen, Lan Chen · 2022 · ACS Applied Polymer Materials
  30. How can MSI enhance our understanding of ASO distribution?
    Laura van der Vloet, Pierre Barbier Saint Hilaire, Christophe Bouillod, Emre Mehmet Isin, Ron M. A. Heeren, Michiel Vandenbosch · 2024 · Drug Discovery Today
  31. Therapeutic suppression of Tubb4a rescues H-ABC leukodystrophy
    Sunetra Sase, Julia Liao Hacker, Prabhat R. Napit, Anjali Bhagavatula, Sarah Woidill, Annemarie D’Alessandro, Marisa A. Jeffries, Akshata Almad, Asako Takanohashi, Quasar Saleem Padiath et al. · 2026 · Molecular Therapy
  32. Estimation of human brain fluid clearance using intrathecal imaging contrast agents
    Per Kristian Eide, Aslan Lashkarivand, Susanne Sørensen Hernes, Geir André Ringstad, Markus Herberg Hovd · 2026 · Fluids and Barriers of the CNS
  33. Targeting neuroinflammation and neurodegeneration in Parkinson’s disease: Emerging natural and synthetic therapeutic strategies
    Safia Arbab, Hanif Ullah, Yanting Han, Jiao Zhou, Ka Li · 2026 · Ageing Research Reviews
  34. ATF3/SOX11-regulated FST activates IGF1R–ERK/AKT–Sp1 signaling to sustain trigeminal neuropathic pain
    Yuejuan Ling, Bing Zhu, Zuo-hao Yao, Ling-Jie Ma, Lin-peng Zhu, Jing Zhang, Fei-fei Xu, Hao Wu, Lulu Ji, Yong‐Jing Gao · 2026 · Acta Pharmacologica Sinica
  35. α-Synuclein burden amplification in Parkinson’s disease: a unified genetic, molecular, and cellular framework
    Sachiko Noda, Nobutaka Hattori · 2026 · Frontiers in Neurology
  36. MiR-129-5p: a novel therapeutic target for amyotrophic lateral sclerosis?
    Zachary C. E. Hawley, Danae Campos‐Melo, Michael Joseph Strong · 2020 · Non-coding RNA Investigation
  37. Antisense Oligonucleotide Therapy for Progressive Myoclonus Epilepsies
    Silvia Nitschke, Berge Arakel Minassian · 2024
  38. Translocation of Oligonucleotide–Oligosaccharide Complexes into Cells of the Brain
    Н. Н. Дыгало, Tatyana S. Kalinina, Dmitriy A. Lanshakov · 2018 · Doklady Biochemistry and Biophysics
  39. Antisense-Oligonukleotide I
    Claudia D. Wurster, Albert Christian Ludolph, Denise Lehmann, Heiko Graf · 2018 · Nervenheilkunde
  40. Investigation of Brain Functions Using Genetically Encoded Tools
    Н. Н. Дыгало · 2020 · Neuroscience and Behavioral Physiology
  41. Current Emerging Therapy for Amyloidosis Neuropathy
    Yung‐Chih Cheng · 2020 · Neuro - Open Journal
  42. Antisense-Oligonukleotide II
    DOROTHEE LEHMANN, AC Ludolph, Claudia D. Wurster, Heiko Graf · 2018 · Nervenheilkunde
  43. Elucidating the consequence and cause of microRNA dysregulation in amyotrophic lateral sclerosis (ALS)
    Zachary C. E. Hawley · 2020 · Scholarship@Western (Western University)
  44. Zgłębiając zawiłości struktur, funkcji i lekowalności cis motywów RNA u koronawirusów
    Joanna Sztuba-Solińska, Devadatta Gosavi · 2021 · Postępy Biochemii
  45. Medicinal Applications of Antisense Oligonucleotides: A Review
    Kavya Pandiri, Mohammed Abdul Samad, Nadeem Abbas Gulamus, Hajera Khanam · 2020 · International Journal of Applied Pharmaceutical Sciences and Research
  46. Faculty Opinions recommendation of Emerging new concepts of degrader technologies.
    Peter R Bernstein · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  47. Faculty Opinions recommendation of Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
    Alexandra Dürr · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  48. Faculty Opinions recommendation of Targeting RNA: A transformative therapeutic strategy.
    Sue Fletcher · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  49. Evaluating the efficacy of commercially available antisense oligonucleotides to reduce mouse and human tau in vivo
    Pranav Vemula, Kathleen M. Schoch, Timothy M. Miller · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Nucleic Acid Pharmaceutical Agents
    Rebecca A. Kohnken, Carole E. Harbison, Stéphanie Klein, Jeffery A. Engelhardt · 2023 · Elsevier eBooks
  51. ESCLEROSE LATERAL AMIOTRÓFICA (ELA): MECANISMOS, DIAGNÓSTICO E POSSÍVEIS TRATAMENTOS
    Maria Clara Oliveira Padilha Diniz, Adélcio Machado dos Santos, Barbara Gabrielly Galindo Guimarães Tribuzi Lula, Fernando Portes Peixoto, Francisco Luan Nogueira Alves, Gabriela Pereira Valadares, Ísis Cavalcante Amaral de Siqueira, Ivna Rocha Bastos, Lívia Maria Figueiredo Teles de Araújo, Lucas Galvão Carvalho et al. · 2023 · Revista Foco
  52. Preclinical Evaluation of Neuraxial Drugs for Safety
    Tony L. Yaksh, Robert B. Boyd, Orion P. Keifer · 2023 · Springer eBooks
  53. Klinik Nöroloji
    Mehmet Türkay Karcı, Erdem Özyurt, Merve Bahar Ercan, Safiye Gül Kenar, Filiz Demirdöğen, Betül Özenç, Özlem Ergin Beton, Nur Türkmen, Mustafa Şen, Mustafa Açıkgöz et al. · 2022 · Akademisyen Kitabevi eBooks
  54. Therapeutic strategies based on genetic interventions
    Rena C. Baek, Patrick F. Finn, Paolo G.V. Martini · 2024 · Elsevier eBooks
  55. Artemia Cyst Production in Solar Earthen Ponds in Vinh Chau, Vietnam, and Its Associated Microbiome
    Tung Hoang, Binh Thai Nguyen, Thu Thi Minh Vo, Trung Tien Le, Long Minh Tran · 2025 · Aquaculture Research
  56. Insights From a Scoping Review and Bibliometric Analysis of Trends and Advances in Biomarker Research: The Role of MicroRNAs in Cognitive Decline Across Neurodegenerative Diseases
    Samuel Reyes-Long, Ernesto Roldán-Valadéz, José Luis Cortes-Altamirano, Denise Clavijo‐Cornejo, Alfonso Alfaro-Rodríguez · 2025 · Cureus
  57. Antisense oligonucleotide of cargo adaptor BICD2 long-term effectively alleviates neuropathic pain via activation of PSD95 in the mouse spinal dorsal horn
    Zixuan Wu, Yang Xu, Jing Xie, Gan Ma, Yu-Xia Li, Tong Yang, Jia-Hui Liang, Yang Li, Qihui Wang, Ling-Yun Hao et al. · 2025 · Neuropharmacology
  58. Additional file 5 of CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma
    Liu, S. John, Martina Malatesta, Brian V. Lien, Parna Saha, Shivani S. Thombare, Hong, Sung Jun, Leslie Pedraza, Koontz, Mark, Kyounghee Seo, Max A. Horlbeck et al. · 2020 · Figshare
  59. Additional file 1 of CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma
    Liu, S. John, Martina Malatesta, Brian V. Lien, Parna Saha, Shivani S. Thombare, Hong, Sung Jun, Leslie Pedraza, Mark Koontz, Kyounghee Seo, Max A. Horlbeck et al. · 2020 · Figshare
  60. Antisense Molecules: Design, Chemistry, and Therapeutic Innovations
    Prema Vediappan, Swetha Aravamudhan, Jocelyn Olivia Prabhakar David, Abitha Sri Ganapathy, Suryalakshmi Guhanathan · 2026 · Mini-Reviews in Medicinal Chemistry
  61. Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA
    Ayşe Yeşbek Kaymaz, Gamze Bora, Hayat Erdem‐Yurter, Christopher Grunseich · 2026 · Genes
  62. Thérapie génique pour l’amyotrophie spinale à l’aide de vecteur AAV
    Aurore Besse · 2019
  63. Le développement préclinique des tcDNA pour la Dystrophie Musculaire de Duchenne
    Philippine Aupy · 2019
  64. Targeting ZNF703 in Luminal BBreast cancer by Antisense Oligonucleotides
    Sandra Oluchi Udu-Ituma · 2023
  65. Protein kinase C in neurodegenerative disorders
    Azadeh Hekmat, Ali Akbar Saboury · 2026 · Elsevier eBooks
  66. The Enigma of Big Tau Exon 4a: Genomic Architecture, Biophysical Identity, and Unique Evolutionary Mechanisms
    Itzhak Fischer · 2026 · Biomolecules
  67. Immune cells and nanotechnology: Innovations in therapy
    Ruth Naomi, Santhra Segaran Balan, Saiful Irwan Zubairi, Shariff Halim, Pamela Rosie David, Roslee Rajikan · 2026 · Elsevier eBooks
  68. Experimental epilepsy models for mechanistic investigation and translational research
    Ali Osman Arslan, Sevdenur Uzun, Güven Akçay · 2026 · Discover Neuroscience
  69. Recent Innovations in Drug Delivery Systems for Amyotrophic Lateral Sclerosis: Past, Present and Future
    Dhvani Padhiyar, Shital Butani, Tushar Vyas, Amit Mukharya, Amarjitsing Rajput · 2026 · AAPS PharmSciTech
  70. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
    Tejal Aslesh, Toshifumi Yokota · 2026 · Methods in molecular biology
  71. Olezarsen for the Treatment of Hypertriglyceridemia
    Antonio Sebastian Hernandez Rodriguez, Toshifumi Yokota · 2026 · Methods in molecular biology
  72. Development of Antisense Gapmers for the Treatment of Huntington’s Disease
    Tejal Aslesh, Toshifumi Yokota · 2026 · Methods in molecular biology
  73. Biophysics-informed computational framework for predicting antisense oligonucleotide knockdown efficacy under small-data constraints
    Risha Guha, Shawn Kim, Anwita Bandaru, Nithika Vivek · 2026 · Frontiers in Systems Biology
  74. New Treatments for Amyloidosis Neuropathy
    Yung‐Chih Cheng · 2025 · Neuro - Open Journal